



# Roundtable Session: Clinical Trial Design and Participation

Professor Olivier Lambotte  
Department of Clinical Immunology  
Hôpital Bicêtre  
ImVA Inserm/CEA U1184  
Université Paris Sud

IAS HIV Cure & Cancer Forum  
Paris, France





COI



- BMS
- MSD
- Astra Zeneca
- Janssen



# HIV infection and Cancer



- Why are we talking about these two diseases today?
- Two major causes of death
- Affect anyone from 0 to 99 years-old, everywhere in the world
- The immune system is unable to eliminate cancer cells and HIV-infected cells
- BUT...



# HIV infection and Cancer



- The two diseases are different !
- The causes are different: a tumor cell versus a virus
- The diseases are different: one virus versus dozens of different cancers
- HIV cure is not possible today but a small cancer can be cured by surgery for example
- The physicians are different: the oncologist versus the infectious disease specialist (they “think” different...)
- The treatments are different: cytotoxic chemotherapy, radiotherapy, surgery versus antiretroviral drugs
- Are the patients the “same”? They “have” (could have) a different way of thinking their disease
  - HIV: a chronic disease with ART
  - Cancer: a deadly disease if you have a metastatic disease



Think different ?



# HIV infection and Cancer



- The two diseases share many similarities!

1/ Major improvement of survival (1997-2017)

- For HIV infection with combined ART
  - For some cancers and even metastatic cancers thanks to immunotherapies
- = Long-term survival for both

[J Acquir Immune Defic Syndr. 200](#)

**HIV-infected adults antiretroviral therapy**

[Lewden C<sup>1</sup>, Chene G, Morlat J et al. \*et les Hepatites Virales \(ANRS\) CO3 AQUITAINE Study Group.\*](#)

**Cancer Therapy: Clinical**

*See commentary by Postow et al., p. 1821*

**CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma**

Peter A. Prieto, James C. Yang, Richard M. Sherry, Marybeth S. Hughes, Udai S. Kammula, Donald E. Catherine L. Levy, Steven A. Rosenberg, and Giao Q. Phan

5-years Survival: 23% - 25%

15 patients in complete response

**Long-term combination**

[Centrale de Recherches sur le Sida et les Hepatites Virales \(ANRS\) CO3](#)



# HIV infection and Cancer



- The two diseases share many similarities!

2/ The “cure” is limited by the persistence of rare cells

- Intrinsic properties favouring persistence and survival
- Defects of the immune system

=Common mechanisms of persistence for HIV and cancer cells

3/ Cure strategies share drugs

- Targeting the infected/cancer cell
  - iHDACs, DNA methylation inhibitors, JAK inhibitors...
- Boosting the immune system
  - Immunotherapies (anti-PD1...), TLR agonists, IDO inhibitors...



# HIV infection and Cancer



- The management of these two diseases shares many similarities!

## 4/ Evolution of the therapeutic strategy

- Small pilot studies (phase I/II) with proof of concept
  - Testing Latency Reversing Agents (LRA) in HIV infection
  - Testing new cancer strategies
- Taking into account new adverse events
  - Those of LRA in HIV infection
  - Those of immunotherapies in cancer





# HIV infection and Cancer



- The two diseases share many similarities!

## 5/ Goals are the same

- The Cure for all patients everywhere
- Get access to costly treatments can be very difficult and this should be improved
- Role of the patients associations and community is determinant for these questions to help physicians

People have to speak together: the roundtable



# Speakers



# Jintanat ANANWORANICH



Jintanat ANANWORANICH, MD,  
PhD  
Associate Director for Therapeutics  
Research,  
U.S. Military HIV Research Program

## Research in

- Pediatric HIV
- Acute HIV
- HIV remission
- Neuro HIV
- Thailand

IAS HIV Cure & Cancer Forum  
Paris, France



# Jean Philippe SPANO



Jean-Philippe SPANO, MD, PhD  
Professor in Medical Oncology  
Head of Department of Medical  
Oncology Pitie-Salpetriere Hospital,  
Paris  
Pierre et Marie Curie University Paris,  
France

## Research in

- Breast, GI cancer, HIV cancer
- Head of CancerVIH national network, and the French rare cancer group of Institut du Cancer (InCa)

IAS HIV Cure & Cancer Forum  
Paris, France



# Thomas S ULDRICK



Thomas Uldrick, M.D., M.S.  
Clinical Director,  
HIV & AIDS Malignancy Branch  
Center for Cancer Research, NCI

## Research in

- KSHV-associated Malignancies
- HIV and Cancer
- Cancer Immunotherapy in Patients with HIV
- South Africa



# Michael LOUELLA



community engagement  
for

**W** AIDS CLINICAL TRIALS UNIT  
UNIVERSITY of WASHINGTON



HIV cure  
research

+

community-based  
participatory research

+

social  
media



# Gilliosa SPURRIER-BERNARD



## MELANOMA PATIENTS NETWORK EUROPE

1. patients first
  2. solutions, not problems
  3. data, not opinions
- and*
4. if you don't do it- no one will

MELANOMEFrance



**MELANOMEFrance**  
Les Patients comme Partenaires